Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
D 81.28 0.31% 0.25
INCY closed up 0.31 percent on Wednesday, May 5, 2021, on 1.53 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Down
Historical INCY trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish 0.31%
Fell Below 50 DMA Bearish 0.31%
MACD Bearish Signal Line Cross Bearish 0.31%
Stochastic Sell Signal Bearish 0.31%
Expansion Pivot Sell Setup Bearish Swing Setup 0.31%
Wide Range Bar Range Expansion 0.31%
Earnings Movers Other 0.31%
Older End-of-Day Signals for INCY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 7 hours ago
Up 2% about 12 hours ago
Rose Above 50 DMA about 12 hours ago
Up 1% about 12 hours ago
50 DMA Support 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Incyte Corporation Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Solid Tumors Chemical Compounds Organic Compounds Inflammation Psoriasis Pancreatic Cancer Hematologic Malignancies Janus Clinical Trial Product Diabetic Nephropathy Myelofibrosis Janus Kinase Inhibitor Clinical Trial Products Morpholines Nitriles Polycythemia

Is INCY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 110.365
52 Week Low 75.52
Average Volume 1,090,184
200-Day Moving Average 87.72
50-Day Moving Average 81.23
20-Day Moving Average 83.22
10-Day Moving Average 84.30
Average True Range 2.12
ADX 11.31
+DI 16.64
-DI 24.26
Chandelier Exit (Long, 3 ATRs ) 79.92
Chandelier Exit (Short, 3 ATRs ) 84.79
Upper Bollinger Band 87.17
Lower Bollinger Band 79.26
Percent B (%b) 0.25
BandWidth 9.50
MACD Line 0.46
MACD Signal Line 0.78
MACD Histogram -0.3192
Fundamentals Value
Market Cap 17.8 Billion
Num Shares 219 Million
EPS 1.87
Price-to-Earnings (P/E) Ratio 43.44
Price-to-Sales 7.58
Price-to-Book 7.82
PEG Ratio 0.85
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 84.19
Resistance 3 (R3) 84.48 83.81 83.71
Resistance 2 (R2) 83.81 83.07 83.66 83.54
Resistance 1 (R1) 82.54 82.61 82.21 82.25 83.38
Pivot Point 81.87 81.87 81.70 81.72 81.87
Support 1 (S1) 80.60 81.13 80.27 80.31 79.18
Support 2 (S2) 79.93 80.67 79.78 79.02
Support 3 (S3) 78.66 79.93 78.86
Support 4 (S4) 78.37